Revive Therapeutics Ltd. announced that it has signed a collaboration agreement with Attwill Medical Solutions LP ("AMS") for the clinical and commercial development of the Company's next-generation lyophilized formulation of Bucillamine. AMS is one of the medical lyophilizers in the U.S., with cGMP facilities and dryers that can lyophilize volumes ranging from 1 to 2,000 liters per cycle. The collaboration between Revive and AMS will support the technology transfer of the lyophilized formulation of Bucillamine from the University of Waterloo ("UW") to AMS. After completing the technology transfer, AMS will begin the development and clinical trial manufacturing of lyophilized
Bucillamine under GMP. The Company expects to have its novel lyophilized Bucillamine ready for clinical evaluation in 2024. To recap, the UW research team has improved the solubility of Bucillamine. Subsequent lyophilization has resulted in more than double enhancement of solubility, which would unlock the therapeutic utility of Bucillamine. Specifically, the lyophilized Bucillamine may support the continuation of the research project the Company has with the Defence R&D Canada - Suffield, an agency of the Canadian Department of National Defence, to evaluate Bucillamine as a potential treatment for nerve agent exposure. Also, Revive and AMS will prepare plans for potential commercial scale-up to support public health medical emergencies, including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. In addition, as a potent antioxidant and anti-inflammatory, Bucillamine may be helpful for orphan indications in rare inflammatory disorders such as ischemia-reperfusion injury (i.e. organ transplantation), which the FDA granted orphan drug designation for in 2022.